NOLVADEX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Nolvadex, and when can generic versions of Nolvadex launch?
Nolvadex is a drug marketed by Astrazeneca and is included in one NDA.
The generic ingredient in NOLVADEX is tamoxifen citrate. There are sixteen drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the tamoxifen citrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nolvadex
A generic version of NOLVADEX was approved as tamoxifen citrate by ACTAVIS LABS FL INC on February 20th, 2003.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NOLVADEX?
- What are the global sales for NOLVADEX?
- What is Average Wholesale Price for NOLVADEX?
Summary for NOLVADEX
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Clinical Trials: | 75 |
DailyMed Link: | NOLVADEX at DailyMed |
Recent Clinical Trials for NOLVADEX
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Jose Pablo Leone | Phase 2 |
Translational Breast Cancer Research Consortium (TBCRC) | Phase 2 |
Eli Lilly and Company | Phase 2 |
US Patents and Regulatory Information for NOLVADEX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astrazeneca | NOLVADEX | tamoxifen citrate | TABLET;ORAL | 017970-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Astrazeneca | NOLVADEX | tamoxifen citrate | TABLET;ORAL | 017970-002 | Mar 21, 1994 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for NOLVADEX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Astrazeneca | NOLVADEX | tamoxifen citrate | TABLET;ORAL | 017970-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
Astrazeneca | NOLVADEX | tamoxifen citrate | TABLET;ORAL | 017970-002 | Mar 21, 1994 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for NOLVADEX
See the table below for patents covering NOLVADEX around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Denmark | 124677 | ⤷ Sign Up | |
France | 1502607 | Nouveaux dérivés alkéniques | ⤷ Sign Up |
United Kingdom | 1146405 | ⤷ Sign Up | |
Germany | 1468088 | ⤷ Sign Up | |
Germany | 1768020 | ⤷ Sign Up | |
Denmark | 118655 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |